RCOR has been the subject of several other reports. Robert W. Baird started coverage on shares of Renovacor in a research report on Monday, September 12th. They set an outperform rating for the company. BTIG Research assumed coverage on Renovacor in a report on Wednesday, September 14th. They set a buy rating on the stock. Finally, Lifesci Capital reaffirmed an outperform rating on shares of Renovacor in a report on Thursday, June 16th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $21.00.
Renovacor Price Performance
RCOR opened at $2.18 on Tuesday. The company’s 50 day simple moving average is $1.86 and its 200-day simple moving average is $2.65. Renovacor has a one year low of $1.34 and a one year high of $10.47. The stock has a market capitalization of $37.64 million, a P/E ratio of -2.99 and a beta of 0.09.
Institutional Investors Weigh In On Renovacor
Renovacor Company Profile
Renovacor, Inc, a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM).
- Get a free copy of the StockNews.com research report on Renovacor (RCOR)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Renovacor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovacor and related companies with MarketBeat.com's FREE daily email newsletter.